Rigel Pharmaceuticals (RIGL) Change in Receivables (2014 - 2026)

Rigel Pharmaceuticals' Change in Receivables history runs 12 years deep, the most recent figure standing at -$1.8 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 2573.53% year-over-year to -$1.8 million; the TTM figure through Mar 2026 stood at $8.4 million (down 40.16% YoY), while the FY2025 annual figure was $10.1 million, down 8.29% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.8 million, down from $5.8 million in the prior quarter.
• The five-year high for Change in Receivables was $24.8 million in Q4 2022, with the low at -$11.0 million in Q1 2023.
• The 5-year median for Change in Receivables is $1.4 million (2024), against an average of $2.0 million.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables jumped 5054.89% in 2022, then slumped 4621.55% in 2023.
• Rigel Pharmaceuticals' Change in Receivables stood at $24.8 million in 2022, then tumbled by 71.75% to $7.0 million in 2023, then surged by 57.62% to $11.0 million in 2024, then sank by 47.12% to $5.8 million in 2025, then tumbled by 131.14% to -$1.8 million in 2026.
• Business Quant data shows RIGL's Change in Receivables at -$1.8 million in Q1 2026, $5.8 million in Q4 2025, and $6.0 million in Q3 2025.